A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Diseases Of The Digestive System
What is the purpose of this trial?
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
- Ages18 years and older
- Trial withAbbVie Inc.
- Start Date10/30/2017
- End Date04/29/2027
- Last Updated06/22/2018
- Study HIC#1506016096REG